advanced tumors
Conditions
Interventions
Observation group:None
Sponsors
The Fifth Affiliated Hospital, Sun Yat-sen University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Willing to voluntarily sign an informed consent form; 2.Age > 18 years; 3.Gender not limited; 4.ECOG performance status score = 2, with an expected life span greater than 12 weeks; 5.Inoperable advanced tumors, including all patients with M1 stage according to TNM staging, all patients with recurrence after radical treatment, or patients with locally advanced disease; 6.Intended to undergo at least 4 cycles of standard radiotherapy, chemotherapy, targeted therapy, or monotherapy or combination therapy of immunotherapy, including patients in the first or second line; 7.At least one measurable lesion based on the RECIST 1.1 criteria for solid tumor response evaluation.
Exclusion criteria
Exclusion criteria: 1.Pregnant or breastfeeding women; 2.Known human immunodeficiency virus (HIV) infection or history of organ transplantation; 3.Severe uncontrolled underlying diseases, such as severe cardiopulmonary insufficiency, uncontrolled infections, etc.; 4.Patients with active autoimmune diseases requiring systemic treatment (using corticosteroids, immunosuppressants, etc.); Replacement therapies (such as thyroid hormone, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) are not considered a form of systemic treatment; 5.Patients with severe hepatic or renal dysfunction, or cardiac insufficiency prior to treatment; 6.Patients with poor compliance to treatment, or incomplete medical records; 7.Patients deemed unsuitable for this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Study the correlation between baseline NK cell activity, circulating tumor cell count, and objective response rate (ORR) after advanced cancer treatment;Analyzing the changes in NK cell activity and circulating tumor cell count in patients before treatment and upon developing resistance (progression);Monitoring the correlation between changes in NK cell activity and circulating tumor cell count during treatment and the objective response rate (ORR) after treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Study the relationship between the dynamic changes in NK cell activity and circulating tumor cell count.;Study the relationship between the dynamic changes in NK cell activity and circulating tumor cell count and the treatment.;Study the correlation between the dynamic changes in NK cell activity, TBNK count, circulating tumor cell count, and progression-free survival (PFS), disease control rate (DCR), and duration of response (DOR).; | — |
Countries
China
Contacts
Public Contactzeng qi
The Fifth Affiliated Hospital, Sun Yat-sen University
Outcome results
None listed